Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOXTROT: Osocimab for VTE Prevention in TKA
NCT03276143Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2017
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, single-blind trial of osocimab in venous thromboembolism (VTE) (8 arms), sponsored by Bayer. Primary endpoints: Incidence of Venous Thromboembolism and Incidence of Major and Clinically Relevant Non-Major Bleeding. Started Sep 2017; status: completed.
02
Drugs
osocimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03276143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276143.